Clinical Trial Update: Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study [Phase 3]

View source ↗

Summary

An 8-week pilot Phase 3 trial evaluating cannabidiol for anxiety disorders, including generalized anxiety disorder and social anxiety disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Agoraphobia
• Generalized Anxiety Disorder
• Panic Disorder
• Social Anxiety Disorder

Drugs mentioned

• Cannabidiol (cannabidiol)

Snippet

Sponsor: McMaster University | Conditions: Generalized Anxiety Disorder, Social Anxiety Disorder | Phase 3 | Status: UNKNOWN